Napronil Plus500 mg+20 mg

Napronil Plus 500 mg+20 mg Magnesium is a fixed-dose combination tablet that pairs a non-steroidal anti-inflammatory drug (NSAID) with a proton pump inhibitor (PPI) in a single delayed-release formulation. It is designed for people who need long-term, regular-dose NSAID therapy for arthritis but are also at risk of developing stomach (gastric) ulcers from that NSAID use. This combination tablet is indicated for the relief of the signs and symptoms of the following conditions, and for reducing the risk of NSAID-associated gastric ulcers in patients who need ongoing anti-inflammatory treatment.

1. Osteoarthritis

Napronil Plus 500 mg+20 mg Magnesium is used to relieve joint pain, stiffness, and swelling caused by osteoarthritis, the most common form of arthritis resulting from wear-and-tear of the cartilage that cushions the joints. It is commonly prescribed for osteoarthritis affecting the knees, hips, hands, and spine.

2. Rheumatoid Arthritis

This combination tablet helps control the pain, swelling, and morning stiffness associated with rheumatoid arthritis, an autoimmune condition in which the body's immune system mistakenly attacks the lining of the joints, leading to chronic inflammation and, over time, joint damage.

3. Ankylosing Spondylitis

It is also indicated for ankylosing spondylitis, a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints, causing chronic back pain and progressive stiffness. Regular NSAID use is a cornerstone of long-term symptom management in this condition.

4. Juvenile Idiopathic Arthritis (Adolescents)

In adolescent patients 12 years of age and older, this tablet may be used to manage the joint pain and inflammation of juvenile idiopathic arthritis, with the dose adjusted according to body weight.

5. Reducing the Risk of NSAID-Associated Gastric Ulcers

A key feature of this combination is its built-in gastroprotection. The esomeprazole component decreases gastric acid secretion, which lowers the risk of developing stomach and duodenal ulcers in patients who require regular naproxen therapy and are at risk of NSAID-associated gastrointestinal complications, such as older adults or those with a prior history of ulcers.

Important: This medicine is intended for chronic, scheduled use in arthritic conditions and is not designed for occasional, on-demand pain relief or acute pain, since the naproxen component is released only after the esomeprazole layer dissolves. Always take this medicine exactly as prescribed by a registered physician.

Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Napronil Plus 500 mg+20 mg Magnesium is formulated as a sequential-release tablet. It consists of an immediate-release esomeprazole magnesium outer layer surrounding an enteric-coated naproxen core. This unique design means esomeprazole is released first into the stomach, raising the gastric pH before the naproxen core moves into the small intestine, where it dissolves and is absorbed. This sequencing is what allows the tablet to relieve arthritic pain while actively protecting the stomach lining at the same time.

Naproxen: Anti-Inflammatory and Analgesic Action

Naproxen is a propionic acid-derivative NSAID with analgesic (pain-relieving), antipyretic (fever-reducing), and anti-inflammatory properties. Its mechanism of action is believed to be related to the inhibition of prostaglandin synthesis through non-selective blockade of the cyclooxygenase (COX-1 and COX-2) enzymes. Prostaglandins are chemical messengers that sensitise nerve endings to pain and drive the inflammatory response, so reducing their production helps relieve joint pain, swelling, and stiffness in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Esomeprazole: Gastric Acid Suppression

Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion through specific inhibition of the H+/K+-ATPase enzyme (the "proton pump") located in the gastric parietal cells of the stomach lining. By acting on this final, common step of acid production, esomeprazole reduces gastric acidity and raises intragastric pH, which both relieves acid-related symptoms and protects the stomach mucosa from the irritant effects of naproxen.

Why the Combination Works Better Than Naproxen Alone

NSAIDs such as naproxen can damage the protective mucus layer of the stomach and reduce the production of protective prostaglandins within the gastric lining itself, which is why long-term NSAID use carries a risk of peptic ulcers and gastrointestinal bleeding. By co-delivering a proton pump inhibitor in the same tablet, this fixed-dose combination is designed to maintain the anti-inflammatory and analgesic benefit of full-dose naproxen while significantly lowering the incidence of NSAID-associated gastric ulcers compared with naproxen taken alone.

Pharmacokinetics

Because of the delayed-release naproxen core, this tablet has a slower onset of pain relief than immediate-release naproxen and is therefore intended for scheduled, ongoing use in chronic arthritic conditions rather than for fast relief of acute or breakthrough pain. Naproxen is highly protein-bound in plasma and is metabolised mainly in the liver, with excretion predominantly via the kidneys. Esomeprazole is also extensively metabolised in the liver, chiefly through the CYP2C19 and, to a lesser extent, CYP3A4 enzyme pathways, and is largely cleared from the body within a day of dosing.

Napronil Plus 500 mg+20 mg Magnesium can interact with a number of other medicines because of the combined effects of its NSAID and proton pump inhibitor components. Always tell your doctor or pharmacist about all prescription drugs, over-the-counter medicines, and supplements you are taking before starting this tablet.

Interactions With Other Medicines

Interaction With Food

Taking this tablet together with a high-fat meal does not change the overall extent of naproxen absorption, but it significantly delays the time to reach peak plasma concentration (Tmax) by around 10 hours and reduces the peak plasma concentration (Cmax) by about 12%. For this reason, the tablet should be taken at least 30 minutes before a meal to ensure predictable, timely pain relief.

Immediate-release esomeprazole is included in this tablet specifically to decrease the incidence of gastrointestinal side effects from naproxen. Clinical studies have shown that this combination significantly reduces the occurrence of gastric ulcers and other NSAID-associated upper gastrointestinal adverse events compared with naproxen taken alone. Even so, side effects can still occur, and patients should be aware of the following.

Common and Notable Side Effects

When to seek medical attention: Stop taking this medicine and contact your doctor immediately if you notice black or bloody stools, vomiting blood or material that looks like coffee grounds, severe or persistent abdominal pain, unexplained weight loss, chest pain, shortness of breath, sudden swelling of the face, lips or throat, or signs of an allergic reaction such as widespread rash or difficulty breathing.

Immediate-release esomeprazole is included in this tablet specifically to decrease the incidence of gastrointestinal side effects from naproxen. Clinical studies have shown that this combination significantly reduces the occurrence of gastric ulcers and other NSAID-associated upper gastrointestinal adverse events compared with naproxen taken alone. Even so, side effects can still occur, and patients should be aware of the following.

Common and Notable Side Effects

When to seek medical attention: Stop taking this medicine and contact your doctor immediately if you notice black or bloody stools, vomiting blood or material that looks like coffee grounds, severe or persistent abdominal pain, unexplained weight loss, chest pain, shortness of breath, sudden swelling of the face, lips or throat, or signs of an allergic reaction such as widespread rash or difficulty breathing.

General Precautions

Combining Napronil Plus 500 mg+20 mg Magnesium with other NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors, should be avoided because of the cumulative risk of serious NSAID-related adverse events. This tablet can be used together with low-dose acetylsalicylic acid (aspirin) when prescribed for cardiovascular protection. Side effects can be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. Risk factors for developing NSAID-related gastrointestinal complications include older age, concomitant use of anticoagulants, corticosteroids, other NSAIDs (including low-dose aspirin), debilitating cardiovascular disease, Helicobacter pylori infection, and a personal history of gastric or duodenal ulcers or upper gastrointestinal bleeding. In patients with conditions such as inducible porphyrias, systemic lupus erythematosus, and mixed connective tissue disease, naproxen should only be used after a careful benefit-risk assessment. Patients on long-term treatment, particularly those treated for more than a year, should be kept under regular medical surveillance.

Use in Older People

Older people have an increased frequency of adverse reactions to naproxen, especially gastrointestinal bleeding and perforation, which may be fatal. The esomeprazole component of this tablet has been shown to reduce the incidence of ulcers in older people, but careful monitoring is still recommended in this age group.

Gastrointestinal Effects

Gastrointestinal bleeding, ulceration, or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. This risk is higher with increasing NSAID doses, in patients with a history of ulcers (particularly if complicated by haemorrhage or perforation), and in older people. Such patients should begin treatment on the lowest available dose. Combination therapy with additional protective agents (for example, misoprostol or another proton pump inhibitor) should be considered for patients who also require concomitant low-dose aspirin or other drugs likely to increase gastrointestinal risk. Patients with a history of GI toxicity, particularly older people, should promptly report any unusual abdominal symptoms, especially signs of GI bleeding, particularly during the initial stages of treatment. Extra caution is advised in patients also taking oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors, or antiplatelet agents such as aspirin. If GI bleeding or ulceration occurs while taking this tablet, treatment should be withdrawn immediately. NSAIDs should be given with care to patients with a history of inflammatory bowel disease such as ulcerative colitis or Crohn's disease, as these conditions may be exacerbated. On the esomeprazole side, dyspepsia can still occur despite the gastroprotective layer, and treatment with proton pump inhibitors may be associated with a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter. As with all acid-blocking medicines, esomeprazole may reduce the absorption of vitamin B12 due to reduced stomach acidity; this should be considered in patients with reduced body stores or other risk factors for vitamin B12 deficiency on long-term therapy.

Cardiovascular and Cerebrovascular Effects

Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure, as fluid retention and oedema have been reported in association with NSAID therapy. Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with this tablet after careful consideration of the risks. Similar caution should be exercised before initiating longer-term treatment in patients with cardiovascular risk factors such as hypertension, hyperlipidaemia, diabetes mellitus, or smoking.

Renal Effects

Long-term administration of NSAIDs, including the naproxen component of this tablet, has been associated with renal papillary necrosis and other forms of kidney injury. Patients with pre-existing renal impairment, dehydration, or those taking other nephrotoxic medicines should be monitored closely.

Naproxen Overdose

Symptoms: Significant naproxen overdose may be characterised by lethargy, dizziness, drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, transient alterations in liver function, hypoprothrombinemia (impaired blood clotting), renal dysfunction, metabolic acidosis, apnoea, disorientation, or vomiting. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur but are rare. Anaphylactoid reactions have been reported following therapeutic ingestion of NSAIDs and may also occur after an overdose. The exact dose that would be life-threatening is not known.

Management: Patients should be managed with symptomatic and supportive care following an NSAID overdose, with particular attention to gastrointestinal effects and renal damage. There is no specific antidote. Haemodialysis does not effectively decrease the plasma concentration of naproxen because of its high degree of protein binding. Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or an osmotic cathartic may be indicated in patients seen within 4 hours of ingestion who have symptoms or who have taken a large overdose. Forced diuresis, urinary alkalinisation, or haemoperfusion are unlikely to be useful due to the drug's high protein binding.

Esomeprazole Overdose

Symptoms: Limited clinical experience with deliberate esomeprazole overdose (doses in excess of 240 mg/day) indicates that symptoms are typically transient. Single doses of up to 80 mg of esomeprazole have been reported as uneventful.

Management: No specific antidote is known for esomeprazole overdose. Esomeprazole is extensively bound to plasma proteins and is therefore not readily removed by dialysis. As with any overdose, treatment should be symptomatic, with general supportive measures as needed.

In case of suspected overdose, seek emergency medical attention or contact a poison control centre immediately. Do not attempt to manage an overdose at home.

• Store at a temperature below 30°C, in a cool, dry place.
• Protect from light and moisture; keep the tablets in their original blister pack or container until ready to use.
• Do not store in the bathroom or near a sink, where humidity is high.
• Keep out of the reach and sight of children.
• Do not use the medicine beyond its expiry date printed on the pack.
• Dispose of any unused or expired tablets safely, in line with local pharmacy or healthcare facility guidance, rather than discarding them in household waste.